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Abstract
Background: Antibiotic prophylaxis is frequently administered in severe trauma. However, the risk of selecting resistant
bacteria, a major issue especially in critical care environments, has not been sufficiently investigated. The aim of the present
study was to provide guidelines for antibiotic prophylaxis for four different trauma-related clinical conditions, taking into
account the risks of antibiotic-resistant bacteria selection, thus innovating previous guidelines in the field.
Methods: The MEDLINE database was searched for studies comparing antibiotic prophylaxis to controls (placebo or no
antibiotic administration) in four clinical traumatic conditions that were selected on the basis of the traumatic event
frequency and/or infection severity. The selected studies focused on the prevention of early ventilator associated
pneumonia (VAP) in comatose patients with traumatic brain injury, of meningitis in severe basilar skull fractures, of wound
infections in long-bone open fractures. Since no placebo-controlled study was available for deep surgical site-infections
prevention in abdominal trauma with enteric contamination, we compared 24-hour and 5-day antibiotic prophylaxis
policies. A separate specific research focused on the question of antibiotic-resistant bacteria selection caused by antibiotic
prophylaxis, an issue not adequately investigated by the selected studies. Randomised trials, reviews, meta-analyses,
observational studies were included. Data extraction was carried out by one author according to a predefined protocol,
using an electronic form. The strength of evidence was stratified and recommendations were given according to the
Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.
Results: Uncertain evidence deserving further studies was found for two-dose antibiotic prophylaxis for early VAP
prevention in comatose patients. In the other cases the risk of resistant-bacteria selection caused by antibiotic
administration for 48 hours or more, outweighed potential benefits.
Conclusions: When accounting for antibiotic-resistant bacteria selection we found no evidence in favour of antibiotic
prophylaxis lasting two or more days in the studied clinical conditions.
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Introduction
In the attempt to investigate antibiotic prophylaxis in several
trauma-related clinical conditions, taking into account the
potential ecological risk, innovating previous approaches, in
February 2013 a meeting of experts was held in Bologna in the
context of the 8th edition of the Trauma Update and Organization
conference.
Infection is the consequence of contamination due to the
contact between normally sterile tissues and microorganisms from
the external environment or from internal sites. The inoculation
occurs when the trauma breaks natural barriers against infections.
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All attempts to reduce the bacterial charge in the tissues should be
made. Cleaning, irrigation, disinfection of wounds, followed by the
appropriate early surgical treatment when indicated, are crucial
for infection prevention. Antimicrobial prophylaxis is only one
element integrating these interventions and should be limited to
the period immediately after the trauma.
One major drawback of exposure to antibiotics is the emergence
of drug-resistant bacteria strains, as the result of selection pressure
on resistant colonizing strains or on bacteria with newly acquired
mutations. Unfortunately, most studies dealing with antibiotic
prophylaxis have not adequately investigated this issue, which is
particularly relevant in critical care settings where bacterial
resistance to antibiotics has become a major problem. Here, we
focused on studies comparing antibiotic prophylaxis and placebo
in reducing infections in several trauma-related conditions taking
into account the risk of antibiotic-resistant bacteria selection to
produce a fair risk/benefit ratio assessment, in contrast with other
guidelines addressing similar issues [1,2].
In the present paper, we report the contents of the review, the
analysis and discussion of the literature, and the conclusions of the
conference.
Methods
The works was organized in three sequential steps:
Step 1: The Coordinating Committee formed by five intensivists
selected an initial list of topics. Head, thorax, abdomen, and limbs
trauma were considered. Because of time constraints (there were
only two days to discuss the issues during the convention) only four
clinical conditions were selected based on traumatic event
frequency and/or infection severity. The scenarios included
antibiotic prophylaxis for 1) early VAP in comatose patients, 2)
meningitis in severe skull fractures, 3) wound infection in long-
bone open fractures (we initially focused on osteomyelitis but
found no study specifically investigating this issue), 4) deep
surgical-site infections in abdominal trauma with hollow viscus
perforation. We also considered but discarded pneumonia in
thoracic contusion, empyema after chest tube insertion, surgical-
site infection for long-bone closed fractures, infection after soft
tissues open injuries, abdominal trauma without bowel perfora-
tion, and inhalation pneumonia in pre-hospital intubation.
The Coordinating Committee then generated the queries for
the literature search and selected the articles fulfilling the criteria
established for each subject. The fundamental criterion, shared by
all the investigated issues, was the comparison between adult
patients subjected to antibiotic prophylaxis and controls. When
such studies were not available comparison between groups
receiving different pharmacological protocols were considered.
The MEDLINE database was searched using the free PubMed
provider. Randomised trials, reviews, meta-analyses, or observa-
tional studies were selected. Pediatric and animal studies, and
articles not written in English, were excluded. The MEDLINE
search covered a period between January 1970 and January 2014.
This search was integrated with the consultation of reference lists
of retrieved articles.
The Coordinating Committee members unanimously selected
the articles after reviewing the abstracts, with the help of one of the
authors with specific expertise in statistics and research method-
ology. Full-texts were then retrieved and a further selection was
carried out.
The statistical and methodological expert also performed data
extraction according to a predefined plan (the protocol was not
pre-registered), using a dedicated electronic form that automati-
cally performed all planed computations and plot generation. The
electronic form was developed ad hoc for this revision, and tested
and refined using the studies on early VAP prevention with
antibiotic prophylaxis.
Data collected included study inclusion criteria, antibiotic class
and dose, duration of prophylaxis, antibiotic-resistant bacteria
selection when investigated, infection rates, and mortality rates
when available, along with information needed for the GRADE
evidence quality assessment.
Data were presented as event rates in treatment arms and
controls, absolute risks, absolute risk reductions, and relative risks.
Adjusted odds ratios were reported when dealing with multivariate
analysis results in observational studies. Numbers needed to treat
were also calculated. Confidence intervals were computed for all
the above measures. Relative risks were graphically represented in
Forest plots.
Design heterogeneity among selected studies advised against
their combination in meta-analyses. For the same reason statistical
approaches to investigate presence of asymmetry and potential
publication bias were not carried out [3].
The queries and the results of the summarised results were
submitted to the External Scientific Advisory Panel, formed by
four intensivists with expertise in the field of infections and trauma
in critical care settings, who discussed them together with
Coordinating Committee members.
Evidence provided by randomised controlled trials (RCTs) and
observational studies was ranked on the basis of the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) criteria. [4–6] The GRADE provides a framework to
guide reviewers for the assessment of the strength of evidence,
taking into account that different reviewers or reviewing groups
can evaluate the same evidence differently. [7] Moreover, it
eliminates automatic links between the strength of the recommen-
dation and the strength of the evidence, leaving to the reviewers
the possibility of grading recommendations based on other
variables relevant to clinical decisions, besides evidence.
The GRADE stratifies quality of evidence on a four-level scale,
ranging from high to very low, [7], in favour or against
intervention. In the middle of this scale an absence of evidence
level was added. This event occurs frequently in studies with small
sample size, where the alternative hypothesis and statistical power
have not been adequately taken into account. In our opinion,
negative results from such studies should thus not be considered
indicative of no effect, but rather of an unresolved issue [8].
The reporting of RCTs was evaluated on the basis of currently
shared standards. [9] We considered quasi-randomised studies, in
which treatment allocation is based on non-random methods such
as alternation, leading to severe bias in regards to sequence
generation and allocation concealment.
Our evaluation of meta-analyses was restrictive, according to
the principle that heterogeneity among studies in terms of
inclusion criteria, study design, study treatment, type of outcome,
which are not accounted for by statistical methods focused on
heterogeneity of outcome rates, [10] should contraindicate the
merging of their results. [11] When dealing with observational
studies we discarded al investigations that reported only crude-
data comparisons without performing adjustment for potential
confounders.
Step 2: The results were presented to the physicians invited to
the symposium - intensivists, infectious disease specialists,
surgeons, emergency physicians, radiologists, and physiatrists –
and the issues were collectively discussed. The discussion was
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audio-recorded and at a later stage revised by members of the
Coordinating Committee to identify and highlight the main
opinions that emerged from the discussion.
Step 3: the scientific advisors and the Coordinating Committee
members formed the jury that provided recommendations that
were presented as preliminary results on the final day of the
conference, but discussed and refined in the following months by
e-mail. A final meeting was held one year after the conference, to
discuss diverging opinions until unanimity was reached. To
develop the recommendations the panel followed the GRADE
framework. This is based on four points: quality of evidence,
balance between desirable and undesirable effects, values and
preferences, uncertainty about whether the intervention represents
a wise use of resources [12].
The GRADE initially attributes a high default level of evidence
to RCTs and a low level to observational studies. [7] RCTs can
then be up- or downgraded according to the following criteria:
study limitations due to insufficient internal validity, indirectness of
evidence, imprecision of results, inconsistency between studies,
and selective publication of studies. [13–17] While the first three
are related to single studies, the last two points take into account
the relation with other studies in terms of inconsistent results and
publication bias, respectively. We added an other criterion which
included other weak features of the study, such as the unbalance in
important variables between study arms in RCTs that may occur
when the sample size is small.
For RCTs the first criterion, i.e. bias, takes into account
allocation concealment and blinding, completeness of follow-up
and adherence to the intention-to-treat principle, premature study
interruptions for benefit, and selective reporting of outcomes. [17]
The last criterion takes into account the existence and availability
of a study protocol or on the clear omission to report important
outcomes. [17] We were not able to comply with this criterion
because, for most RCTs, protocols were not available. For each of
these items, concerns can be serious or very serious, down-scoring
the evidence by one and two points respectively. For example, a
RCT with an initial high-evidence grading can be downgraded to
moderate or low, or even very low, if there are other weak points.
Limits in observational studies can include lack of controls, as in
case series, or, when controls are present, lack of adjustment for
important covariates, which may be unevenly distributed between
study groups [17].
Initially, evidence is rated only one point up when the relative
risk is between 0.5 and 0.2 or between 2 and 5, and two points up
when lower than 0.2 or higher than 5, obviously when dealing
with statistically significant results. However, even in the presence
of large effects, when imprecision is strong (i.e. wide 95%
confidence intervals) and negligible effects cannot be ruled out,
upgrading is not performed. The rating can also be increased
when a dose-response is evident or plausible potential confounders
would only increase the confidence in the results [7,18].
The strength of recommendations can be strong or weak, in
favour or against interventions. [19] Only when an intervention
with a strong likelihood of effectiveness had not been sufficiently
investigated (i.e. absence of evidence as defined above) we
considered the possibility of not giving any recommendation,
although we usually gave a weak negative recommendation in
most cases of absence of evidence, in the light of the limited
resources available.
The conference dealt with four different issues of broad clinical
interest but focusing especially on relevance for critically ill
patients and from the point of view of intensive care unit (ICU)
and emergency department physicians.
To investigate the main undesirable effects of prophylaxis, we
preliminarily performed a systematic research on the effect of short
antibiotic administration on bacterial antibiotic-resistance selec-
tion, to provide a fair assessment of the balance between benefits
and risks. The results of this investigation integrated, when
appropriate, the evidence concerning antibiotic prophylaxis in the
clinical conditions we explored.
A transparent report of the reviewing process and of evidence
grading is provided for each query in the supporting information.
The review was conducted complying with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement recommendations (Table S6 in File S6) [20].
Results
We tried to find an answer to the following question: Does short
antibiotic prophylaxis cause resistant bacteria selection? To do this
we explored the influence of short antibiotic course on resistant
bacteria selection at two levels: at the patient’s level, investigated
before and after exposure, and at the centre level, comparing
restrictive and liberal antibiotic prescription strategies between
centres or within a single centre before and after the policy change.
We also assumed that there is strong evidence that prolonged
antibiotic exposure (say, 7–10 days) increases the risk of
colonization with resistant bacterial strains, [21] and without
formally investigating this issue with the GRADE approach, we
attributed to it a default high level of evidence.
Selection of antibiotic-resistant bacteria in patients
exposed to prophylaxis
The contemporaneous combination of the mutant bacteria and
antibiotic exposure determines the spread of antibiotic-resistant
bacteria. [22] Although patients admitted to the hospital after
trauma are usually young and healthy, given the presence of
resistant bacteria also within the community, the possibility that
they may be already colonized by such strains cannot be ruled out.
[23,24] Moreover, colonization in non-colonized patients can
occur because of newly acquired bacterial mutations, selection of
bacterial resistant strains among heterogeneous populations, [25]
and horizontal transfer, [26] the latter being particularly relevant
in ICU environments. [27] We made an extensive literature
revision focusing on antibiotic-resistant colonization in patients
undergoing short antibiotic treatment, but RCTs in this field were
unavailable. Thus, we had to rely on the few observational studies
found (Table S5 in File S5).
In a study carried out on a cohort of 2,641 patients receiving
antibiotic prophylaxis for cardiac surgery, of 1,094 undergoing
cultures 426 were shown to harbour bacteria resistant to the
antibiotic they were exposed to. Logistic regression, adjusting for
many possible confounders, indicated an increased risk of
resistance selection in case of antibiotic prophylaxis lasting more
than 48 hours. [28] Overall the description of the statistical
procedures was scanty, hindering quality assessment. One major
limitation was that only part of the patients were submitted to
cultures and that physicians in the centre were ‘‘encouraged’’ to
keep antibiotic prophylaxis duration within 48 hours, potentially
introducing selection biases that logistic regression may have not
accounted for. Moreover, colonization status was not assessed
before prophylaxis was administered, so it is not known whether
the patients had previous colonization or acquired the resistant
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pattern during therapy or during the postoperative stay in a high-
risk environment as the ICU.
In a before/after study involving 5 wards, the rate of acquisition
within 30 days from initial antibiotic exposure, was 3% for MRSA
(22/724), 2% for vancomycin-resistant enterococci (VRE) (10/
430), and 1% (11/840) for ciprofloxacin-resistant Pseudomonas
Aeruginosa (CRPA). [29] Forty per cent of newly acquired
colonization with resistant bacteria was detected 48 hours from the
first antibiotic dose. The initial colonization rate was 16% of 864
patients for MRSA, 50% for VRE, and 3% for ciprofloxacin-
resistant Pseudomonas Aeruginosa. Cephalosporins, quinolones,
and macrolides were the antibiotics more frequently administered
(31, 29, 19% of cases, respectively). Absence of control (i.e. patient
not exposed to antibiotics) although not irrelevant was not a major
issue, in our opinion, because we do not expect factors other than
antibiotic pressure to affect the colonization rate within a 48-hour
period. A low colonization rate, as in this study, is still clinically
relevant if we account for the duration and possibility of horizontal
spread of resistant bacterial colonization, especially in environ-
ments such as the ICU [27,30].
Another study investigated 29 patients undergoing cardiac
surgery and 10 coronary angioplasty, receiving prophylaxis for
three days with a first or a second-generation cephalosporin. [31]
Cultures were collected at time 0 and on the third day. The
investigators detected colonization by methicillin-resistant coagu-
lase-negative staphylococci in 36 of 43 cultured sites (84%)
previously not colonized and a quantitative colonization increase
in 17 of 28 sites (61%) harbouring low-level colonization before
antibiotic administration. The main limitation of the study was
that multiple samples were collected from each patient that may
have borne the same resistant bacteria, inflating the final count of
true events. A reliable quantitative estimation of resistant bacteria
selection was hence impossible. This study was also limited by its
small sample size.
Finally, in a study investigating the effect of a five-day course
with clarithromycin, 5 patients colonised by susceptible entero-
coccus strains few days after the end of treatment developed
resistant types, which in 3 cases persisted for one year or more.
[32] Although, almost a case report, this study is indicative of how
antibiotic pressure can select resistant strains and how long the
effects can last over time.
Effect of liberal vs. aggressive antibiotic prescriptive
strategies
The limitation of antibiotics use is widely recognized as an
effective strategy for the reduction in bacterial resistance. [33,34]
However, the role of antibiotic prophylaxis policies, corresponding
to strong limitations in antibiotic use, have never been investigated
in relation to antibiotic-resistance acquisition. Indeed a recent
review concerning the influence of antibiotic exposure on MRSA
diffusion, the shortest period of antibiotic administration consid-
ered was 7 days. [21] In a before/after study dealing with late-
generation cephalosporin administration policy, surgical prophy-
laxis was among the exceptions to restriction, indicating that the
authors did not feel it was significant for the purposes of their
policy [35].
Conclusions: there is low evidence indicating that antibiotic
prophylaxis lasting 48 hours or more is capable of determining the
colonization with resistant bacterial strains, that is the undesirable
effect reported in the text and tables for each of the interventions
under scrutiny.
Question 1: is antibiotic prophylaxis for the prevention of
ventilator-associated lower respiratory tract infections
effective in intubated patients with traumatic head injury
(TBI) and coma, i.e. Glasgow Coma Scale (GCS) #8?
Results: the MEDLINE search provided only three studies, two
RCTs and one observational study, [36–38] all complying with
our inclusion criteria. Although, the studies did not deal
exclusively with TBI patients, the results can be reasonably
extended to this category of patients. The two RCTs are described
in Table 1, Table S1 in File S1, and Figure S1 and tested
respectively a 3-day and a single-day antibiotic prophylaxis. Both
RCTs reported a statistically significant reduction of early-VAP,
but no reduction of late-onset pneumonia and ICU mortality.
Besides other flaws, major limitations of both RCTs were the
absence of blinding, the small sample size and the lack of power to
detect increases in antibiotic-resistant infections in the treatment
group (outcome investigated only in the first RCT). [36]
Moreover, the second RCT was not specifically focused on
comatose patients. [37] The premature interruption of the first
RCT after the first interim analysis when only 38 patients were
randomised, on the basis of the reduction of early-onset
pneumonia incidence in the treatment arm, while no difference
in mortality was detected, is a questionable choice. Finally, the
beneficial effect of the postponement of pneumonia in a phase of
minor vulnerability of the brain in severe brain injury is only
theoretical and was not demonstrated with a robust outcome, such
as the long-term mortality/severe disability rate. The main
undesirable effect, i.e. antibiotic-resistant bacteria selection,
according to the evidence we collected, was likely to occur after
three days of antibiotic administration, while probably irrelevant
when only two doses are given.
The results of a recent observational study, including 129
patients suggested that a single dose of ceftriaxone was an
independent predictor of reduced incidence of early-onset
pneumonia. [38] The regression analysis was performed including
a propensity score and the variable ‘‘antibiotic prophylaxis’’ in a
regression model, but the number of outcomes (overall 15 cases of
early-onset VAP) did not justify the inclusion of the two above
variables according established rules. [39,40] Moreover, the
sample size and the number of events were small, and the model
was underpowered to include potential important covariates
capable of influencing the significance of ceftriaxone administra-
tion in the predictive model. The observational study appeared to
be, hence, unreliable and was not taken into account in our final
evaluation.
Conclusions: The two RCTs had substantial different interven-
tions and outcomes, thus we provided recommendations for two
different queries (Table 2).
Intervention 1. Three-day course with a beta-lactamase-
protected penicillin for the prevention of ventilator-associated
early-VAP in intubated patients with TBI and coma:
Level of evidence in favour: Very low evidence.
Level of evidence against: Low evidence.
Recommendation: Weak against intervention.
Intervention 2. 2-dose wide spectrum antibiotic administra-
tion for the prevention of early-VAP in intubated patients with
TBI and coma.
Level of evidence in favour: Very low evidence.
Level of evidence against: No evidence.
Recommendation: Weak against intervention.
Antibiotic Prophylaxis in Trauma
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very
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Table 1. Antibiotic prophylaxis for early-VAP prevention in comatose patients: patients, interventions, and outcomes.
Desirable effect Undesirable effect Desirable effect
Sample Treatment Control Outcome Outcome quality Outcome Outcome quality
Treatment arm
% (95%-CI)
Controls %
(95%-CI)
Difference %
(95%-CI)
RR
(95%-CI)
Ventilated patients,
cerebral haemorrhage,
GCS #8
Ampicillin-
sulbactam 3-day
course - 19
patients
No
placebo -19
patients
Early VAP Weak, surrogate
of death/severe
disability
Antibiotic- resistant
bacteria selection
not Adequately
investigated
Robust, Clinically
relevant for the
patient/crucial for
the health-care
organization
21.1
(8.5 to 43.3)
57.9
(36.3 to 76.9)
–36.8
(–59.6 to 25.8)
0.36 (0.14
to 0.94)
Ventilated patients,
cerebral haemorrhage,
GCS #12
2-dose
cefuroxime -
50patients
No
placebo - 50
patients
Early VAP Weak, surrogate
of death/severe
disability
Antibiotic- resistant
bacteria selection
not investigated
Robust, Clinically
relevant for the
patient/crucial for the
health-care organization
16
(8.3 to 28.5)
36
(24.1 to 49.9)
–20
(–35.8 to 22.8)
0.44 (0.21
to 0.93)
doi:10.1371/journal.pone.0113676.t001
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Table 2. Antibiotic prophylaxis for early-VAP prevention in comatose patients - Level of evidence and recommendations.
Patients and
intervention Desirable effect Undesirable effect* Benefit/risk profile
Values and
preferences Resource use Recommendation Rationale
Ventilated patients,
cerebral haemorrhage,
GCS#8 –
Ampicillin-sulbactam
3-day course
Very low
evidence in
favour of
intervention
%%%
Low
evidence
against
intervention
%%
Unfavourable Not available Unwise Weak against intervention The benefit/risk ratio was unfavourable.
Resistant bacteria selection was considered a
likely event for a three-day antibiotic course,
a more robust and thus prevalent outcome
compared to early-VAP reduction, a surrogate
of middle term death and severe disability.
Ventilated patients,
cerebral haemorrhage,
GCS#8-2-dose
cefuroxime
Very low
evidence in
favour of
intervention
%%%
No evidence
against
intervention
%%%%
Uncertain Not available Not assessable Weak against intervention The intervention requires further
investigation focused on hard outcomes such
as death and severe disability. The selection
of resistant bacteria appears to be unlikely
with two doses of antibiotic although it
cannot be ruled out. Notwithstanding the
large effect size (RR 0.44), given the high
degree of imprecision a limited reduction of
early VAP (lower 95%-CI = 0.93) is possible,
corresponding to a 2.8 absolute risk
reduction and a NNTB of 36, a small effect at
the price of an excessively high number of
patients to expose to antibiotics, especially in
the context of the ICU.
*Not investigated in the studies, evidence could be found from external sources. NNTB =number needed to treat for benefit.
doi:10.1371/journal.pone.0113676.t002
A
n
tib
io
tic
P
ro
p
h
ylaxis
in
Trau
m
a
P
LO
S
O
N
E
|
w
w
w
.p
lo
so
n
e.o
rg
6
N
o
vem
b
er
2014
|
V
o
lu
m
e
9
|
Issu
e
11
|
e113676
with no blinding and no placebo, and a partial report of the
results. It was carried out on open fractures due to gunshot, with
infections diagnosis not based on cultures. [55] This study was
negative, since 2 cases out of 32 were reported in the single-day
cefazolin group and 2 out of 35 in the group not receiving
antibiotic. We considered this study methodologically too weak to
be considered a reliable source of evidence.
The antibiotic tested in the first two RCTs (Table 5, Table S3
in File S3, Figure S3) were instead dicloxacillin or benzyl
penicillin, [53] and cloxacillin, [54] respectively. In the first study
treatment was continued for 48 hours and, in the second, for ten
days. The influence of prophylaxis on bacterial resistance to
antibiotics was not investigated in any of these studies. We
assumed that a 10-day antibiotic administration would certainly
greatly increase the risk of antibiotic-resistant bacteria selection.
We attributed, instead, a lower level of evidence to a 48-hour
treatment (Table 6).
A 13.3 and 22.6% wound-infection rate decrease was found in
the antibiotic-prophylaxis arms in the two studies, corresponding
respectively to an almost statistically significant result and a fully
statistically significant result. Interestingly, in the second study,
infections occurring within six weeks were considered early
infections, including infections that, reasonably, should have not
been influenced by early antibiotic prophylaxis. In the first study,
instead, the duration of the ‘‘window’’ period was not specified.
The observational study that matched the inclusion criteria
suggested a protective effect of antibiotic prophylaxis, but since it
was based only on the crude infection rate, it was not included in
the analysis [56].
The meta-analysis included, besides the three RCT mentioned
above, two other studies that we excluded because one was written
in German [58] and the other including hand, foot, and fingers
fracture, pediatric patients and gunshot injuries, without perform-
ing any subgroup analysis on long-bone fractures. [59] The meta-
analysis concluded that antibiotic prophylaxis is effective in
reducing wound infections. However, study designs, inclusion
criteria, treatment protocols, and quality of the trials, were so
heterogeneous to question the reliability of their merging in a
single sample. We hence considered this study a potential source of
misleading information.
We did not find any study comparing no antibiotic prophylaxis
with 24-hours antibiotic prophylaxis, an option recommended by
other guidelines presumably on the basis of indirect evidence
[1,2,60,61].
Conclusions: Two different antibiotic strategies were adopted in
the two studies that were included in the final evaluation, leading
to two answers to two different queries (Table 6).
Intervention 1. 2-day antibiotic administration for the
prophylaxis of wound infections (not specifically osteomyelitis).
Level of evidence in favour: No evidence.
Level of evidence against: Low evidence.
Recommendation: Weak against intervention.
Intervention 2. Prolonged (ten-day) antibiotic prophylaxis
for the prevention of wound infections (not specifically osteomy-
elitis).
Level of evidence in favour: Low evidence.
Level of evidence against: High evidence.
Recommendation: Strong against intervention.
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Question 4: is antibiotic prophylaxis indicated to reduce
the risk of deep surgical site infections in patients with
abdominal trauma and enteric abdominal contamination
submitted to emergent surgery?
Results: out of 504 articles resulting from the literature search,
none compared treatment and no-treatment arms. Our results
were consistent with those of two recent Cochrane meta-analyses
that did not find any RCTs investigating the effectiveness of
antibiotic prophylaxis compared to placebo in reducing infections
following penetrating abdominal trauma [62,63].
Since no direct evidence exists with regard to the effectiveness of
antibiotic prophylaxis in abdominal trauma compared to placebo,
under the assumption that antibiotic prophylaxis is effective in
preventing surgical site infections, [64] we oriented the query
towards the duration of antibiotic prophylaxis as it was studied by
three RCTs focused on penetrating abdominal trauma and deep
surgical infections occurrence, [65–67] and excluded a fourth one
because it did not report the rate of deep surgical site infections.
[68] The main limitation of the studies was that only a minority of
the patients had associated hollow viscus injury. Moreover, the
infection rate for those who bore intestinal perforations was not
reported, making it impossible to analyse subgroup performance.
Thus, it was only possible to study the number of events in relation
to the overall sample, including those without perforation. Another
weakness was that no evidence concerning blunt trauma, a
common event in abdominal trauma, was available.
The first two studies dealt almost exclusively with deep surgical
site infections, i.e. intra-abdominal abscess, peritonitis, and
necrotizing fasciitis, while the third one reported disaggregated
data concerning deep and superficial surgical site infections. Thus,
we were able to analyse data concerning deep surgical infections.
The studies recruited 317, 515, and 300 patients respectively, and
infections rates were 10 vs. 8% in the 5-day and 24-hour treatment
arms in the first two studies, and 6% in both arms in the third one
(Table 7). Although the studies were underpowered to detect
clinically meaningful differences in the outcome rate (the power to
detect a 5% difference ranged between 40 and 60% in the three
RCTs), looking at the range of the absolute-difference 95%-
confidence intervals, there is little chance that a clinically relevant
superiority of 5-day prophylaxis is present (Table 7, Table S4 in
File S4, Figure S4). Moreover, on the basis of our specific evidence
assessment, five days of antibiotic administration have a high
probability of determining resistant-bacterial selection unlike a 24-
hour therapy.
In the studies, surgical management was carried out within few
hours from the injury, and early surgery appears to be a
reasonable condition for short (i.e. #24 hours) antibiotic
prophylaxis. We adopted the Infective Disease Society of America
(IDSA) definition of early surgery (i.e. carried out within 12 hours
from trauma). [69] There is currently no clear proof in favour of
this cut-off but it, nevertheless, seems reasonable.
Conclusions: The review was focused on different antibiotic
strategies under the assumption that antibiotic prophylaxis is
effective in reducing infections compared to placebo (Table 8).
Intervention. Administration of 24-hour is equivalent to 5-
day antibiotic prophylaxis for surgical abdominal trauma with
hollow viscus injury and surgical repair within 12 hours of trauma:
Level of evidence in favour: Very low evidence.
Level of evidence against: No evidence.
Recommendation: Weak in favour intervention.
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Table 5. Antibiotic prophylaxis for the prevention of wound infections in long-bone open fractures: patients, interventions, and outcomes.
Desirable effect Undesirable effect Desirable effect
Sample Treatment Control Outcome
Outcome
quality Outcome Outcome quality
Treatment arm
% (95%-CI)
Controls %
(95%-CI)
Difference
%(95%-CI)
RR (95%-
CI)
Long-bone
open fractures
48-hour course,
dicoxacillin or
penicillin - 60
patients
Placebo - 30
patients
Wound infection (not
specifically osteomyelitis)
Weak, Minor
prognostic
relevance
Antibiotic- resistant
bacteria selection,
not investigated by
the study
Robust, Clinically
relevant for the
patient/crucial for the
health-care organization
6.7
(2.6 to 15.9)
20
(9.5 to 37.3)
–13.3
(–31.1 to 0.7)
0.33 (0.1 to
1.09)
Long-bone
open fractures
cloxacillin 10-day
course - 43 patients
Placebo - 44
patients
Wound infection (not
specifically osteomyelitis)
Weak, Minor
prognostic
relevance
Antibiotic- resistant
bacteria selection,
not investigated by
the study
Robust, Clinically
relevant for the
patient/crucial for the
health-care organization
4.7
(1.3 to 15.5)
27.3
(16.3 to 41.8)
–22.6
(–37.6 to 27.3)
0.17 (0.04
to 0.72)
doi:10.1371/journal.pone.0113676.t005
Table 6. Antibiotic prophylaxis for the prevention of wound infections in long-bone open fractures - Level of evidence and recommendations.
Patients and
intervention Desirable effect
Undesirable
effect*
Benefit/risk
profile
Values and
preferences
Resource
use Recommendation Rationale
Long-bone open
fractures - 48-hour
course dicoxacillin or
penicillin
No evidence
in favour
of intervention
%%%%
Low evidence
against
intervention
%%
Unfavourable Not
available
Unwise Weak against
intervention
The study was slightly negative but the power was insufficient to
detect clinically significant differences. Being the result of a
subgroup analysis the effectiveness of the intervention is only
hypothetical. There is evidence of risk for resistant bacteria
selection even with a two-day antibiotic course. Wound infections
(excluding osteomyelitis) are not as relevant an outcome as
resistant bacteria selection, given the potentially high number
needed to treat (Table S3 in File S3).
Long-bone open
fractures - 10-day
course cloxacillin
Low evidence
in favour
of intervention
%%
High evidence
against
intervention
Unfavourable Not
available
Unwise Strong against
intervention
It is common knowledge that 10-day antibiotic prophylaxis has a
very high chance of determining resistant bacteria selection,
which outweighs wound. infections prevention, generating an
unfavourable benefit/risk profile.
*Not investigated in the studies, evidence could be found from external sources.
doi:10.1371/journal.pone.0113676.t006
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Discussion
The main limitation of our study is that the literature search was
limited to the MEDLINE database and only to publications in
English, because of financial constraints. However, the issues we
have dealt with have been largely investigated in previous reviews,
and the guidelines included in the literature we have scrutinized
wee used as an alternative source of references. We are therefore
confident that we did not miss important publications in this field.
It is our firm belief that our recommendations, and guidelines in
general, should not be clinical rules that impose specific clinical
behaviours on doctors, but only indications applicable to an
average patient, and should never replace the complex and
individualised decisional process that physicians follow for
individual patients [70].
In studying the role of antibiotic prophylaxis in trauma we found
that in many cases the studies did not provide sufficient information
for GRADE categories to be fully applied. Specifically, the assessment
of the overall benefit/risk profile requires the comparison between
desirable and undesirable effects. In the case of prolonged antibiotic
prophylaxis (in several scrutinized studies antibiotic were adminis-
tered for three days or more), the undesirable effect is the selection of
antibiotic-resistant bacteria, an outcome not investigated in most of
the studies. [71] Thus we had to integrate studies investigating
exclusively infection prevention with evidence from other sources
dealing with selection of resistant bacteria, a novel approach
compared to other experiences that have proposed a different
interpretation of evidence in this field [1,2].
The risk of resistant mutant selection due to short antibiotic
pressure has not been investigated with RCTs. We had therefore
to rely on before-after studies investigating either the colonization
of single patients after treatment or the effect of antibiotic policies
changes in single centres.
We were able to find observational studies suggesting that a 2/3-
day antibiotic course could already result in the selection of
antibiotic-resistant bacteria. We graded this evidence as low or very
low, due to several limitations of the studies. However, in the face of
similar strength of evidence in favour and against the intervention,
as in the case of the 3-day antibiotic prophylaxis for wound
infections in open-fractures or early-VAP prevention in comatose
patients, we considered the antibiotic-resistant resistant selection the
main concern in terms of clinical impact and social relevance of the
outcome., Antibiotic-resistant bacteria spread constitutes an emer-
gency for the global health-care system, given its high burden of
mortality and resource consume. [72–74] Since resistant mutations
are widespread in hospitals and extending within the community,
the solution to this problem appears to be the restoration of
susceptible bacteria by strongly limiting antibiotic use. [22] Our
concern is that the common use of antibiotics in prophylaxis, even
for short periods, might significantly worsen this problem. Our
recommendations go in this direction.
In conclusion, we would like to mention a striking report from a
neurosurgical centre that in the late 1960s had to face an outbreak
of resistant Klebsiella Aerogenes, which at its peak caused urinary
infections in 1 of 4 patients, respiratory infections in 1 of 8, and 9
cases of meningitis 8 of which were fatal. [75–77] Though antibiotic
treatment was targeted on sensitivity tests and despite the major
increase in antibiotic consumption in the ward between 1966 ad
1969 the outbreak was out of control. As the authors state, ‘‘in
desperation’’, antibiotic use whether for treatment or prophylaxis
was abandoned. This resulted in an immediate reduction of
infections and the elimination of the Klebsiella from the ward
without any serious adverse event being reported as the consequence
of this strategy. This report although deviating from the paradigm of
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evidence base medicine (we are dealing with a single-centre
epidemiological descriptive report with no statistical analysis
performed and no precise design) nevertheless provides a demon-
stration of the effectiveness of a drastic antibiotic containment
strategy, a potential choice when ‘‘the going gets tough’’.
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